Harrow Share Price Today
(NASDAQ: HROW)

Name: Harrow Share Price Today (NASDAQ: HROW) - Harrow Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Harrow share price is $26.25 & ₹2,282.94 as on 6 Mar 2025, 2.30 'hrs' IST

$26.25

▲

0.14

(0.54%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Harrow share price in Dollar and Rupees. Guide to invest in Harrow stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Harrow, along with analyst recommendations, forecasts, and comprehensive financials.

Harrow share price movements

Today's Low: $25.21
Today's High: $26.27
$26.25
3.96%
Downside
Day's Volatility :4.04%
Upside
0.08%
52 Weeks Low: $9.30
52 Weeks High: $59.23
$26.25
64.57%
Downside
52 Weeks Volatility :84.3%
Upside
55.68%

Harrow (HROW) Returns

Period	Harrow Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-29.85%	3.7%	0.0%
6 Months	-34.44%	-2.8%	0.0%
1 Year	132.1%	2.5%	0.0%
3 Years	271.81%	12.9%	-11.6%

Harrow (HROW) Key Statistics

in dollars & INR

Previous Close	$26.11
Open	$25.9
Today's High	$26.27
Today's Low	$25.21
Market Capitalization	$929.9M
Today's Volume	$198.3K
52 Week High	$59.23
52 Week Low	$9.3
Revenue TTM	$169.1M
EBITDA	$2.8M
Earnings Per Share (EPS)	$-0.97
Profit Margin	-19.75%
Quarterly Earnings Growth YOY	-0.64%
Return On Equity TTM	-50.23%

How to invest in Harrow Stock (HROW) from India?

It is very easy for Indian residents to invest directly in Harrow from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Harrow stock in both Indian Rupees (INR) and US Dollars (USD). Search for Harrow or HROW on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Harrow or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Harrow shares which would translate to 0.033 fractional shares of Harrow as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Harrow, in just a few clicks!

Returns in Harrow (HROW) for Indian investors in Rupees

The Harrow stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Harrow investment value today

Current value as on today

₹2,37,044

Returns

₹1,37,044

(+137.04%)

Returns from Harrow Stock

₹1,32,095 (+132.1%)

Dollar Returns

₹4,949 (+4.95%)

Indian investors sentiment towards Harrow (HROW)

-78%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Harrow Stock from India on INDmoney has decreased by -78% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Harrow

Opaleye Management Inc
11.20%
BlackRock Inc
7.13%
Vanguard Group Inc
5.26%
Private Capital Management, LLC
4.76%
BRAIDWELL LP
2.55%
State Street Corp
2.32%

Analyst Recommendation on Harrow

Buy

90%Buy

10%Hold

0%Sell

Based on 10 Wall street analysts offering stock ratings for Harrow(by analysts ranked 0 to 5 stars)

Based on 10 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Harrow Stock (HROW)

What analysts predicted

Upside of 120.5%

Target:

$57.88

Current:

$26.25

Insights on Harrow Stock (Ticker Symbol: HROW)

Price Movement
In the last 1 year, HROW stock has moved up by 132.1%
Increasing Revenue
Revenue is up for the last 3 quarters, 34.58M → 49.25M (in $), with an average increase of 15.0% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -13.56M → -4.22M (in $), with an average increase of 81.5% per quarter

HROW Harrow Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$41.4M	↑ 54.52%
Net Income	$14.6M	↓ 222.03%
Net Profit Margin	35.35%	↑ 80.11%

	FY19	Y/Y Change
Revenue	$51.2M	↑ 23.67%
Net Income	$-2.6M	↓ 117.72%
Net Profit Margin	-5.07%	↓ 40.42%

	FY20	Y/Y Change
Revenue	$48.9M	↓ 4.48%
Net Income	$-3.4M	↑ 31.91%
Net Profit Margin	-7.0%	↓ 1.93%

	FY21	Y/Y Change
Revenue	$72.5M	↑ 48.3%
Net Income	$-18.0M	↑ 426.67%
Net Profit Margin	-24.85%	↓ 17.85%

	FY22	Y/Y Change
Revenue	$88.6M	↑ 22.24%
Net Income	$-14.1M	↓ 21.77%
Net Profit Margin	-15.9%	↑ 8.95%

	FY23	Y/Y Change
Revenue	$130.2M	↑ 46.95%
Net Income	$-24.4M	↑ 73.3%
Net Profit Margin	-18.75%	↓ 2.85%

	Q2 FY23	Q/Q Change
Revenue	$33.5M	↑ 28.22%
Net Income	$-4.2M	↓ 36.34%
Net Profit Margin	-12.64%	↑ 12.81%

	Q3 FY23	Q/Q Change
Revenue	$34.3M	↑ 2.38%
Net Income	$-4.4M	↑ 3.83%
Net Profit Margin	-12.81%	↓ 0.17%

	Q4 FY23	Q/Q Change
Revenue	$36.4M	↑ 6.1%
Net Income	$-9.1M	↑ 108.34%
Net Profit Margin	-25.16%	↓ 12.35%

	Q1 FY24	Q/Q Change
Revenue	$34.6M	↓ 4.86%
Net Income	$-13.6M	↑ 48.28%
Net Profit Margin	-39.22%	↓ 14.06%

	Q2 FY24	Q/Q Change
Revenue	$48.9M	↑ 41.5%
Net Income	$-6.5M	↓ 52.28%
Net Profit Margin	-13.23%	↑ 25.99%

	Q3 FY24	Q/Q Change
Revenue	$49.3M	↑ 0.65%
Net Income	$-4.2M	↓ 34.81%
Net Profit Margin	-8.57%	↑ 4.66%

	FY18	Y/Y Change
Profit	$24.9M	↑ 87.29%

	FY19	Y/Y Change
Profit	$34.4M	↑ 38.49%

	FY20	Y/Y Change
Profit	$34.4M	↓ 0.02%

	FY21	Y/Y Change
Profit	$54.3M	↑ 57.7%

	FY22	Y/Y Change
Profit	$63.2M	↑ 16.49%

	FY23	Y/Y Change
Profit	$90.6M	↑ 43.25%

	Q2 FY23	Q/Q Change
Profit	$23.5M	↑ 31.62%

	Q3 FY23	Q/Q Change
Profit	$24.2M	↑ 3.1%

	Q4 FY23	Q/Q Change
Profit	$25.1M	↑ 3.53%

	Q1 FY24	Q/Q Change
Profit	$24.0M	↓ 4.07%

	Q2 FY24	Q/Q Change
Profit	$36.4M	↑ 51.45%

	Q3 FY24	Q/Q Change
Profit	$37.2M	↑ 2.3%

	FY18	Y/Y Change
Operating Cash Flow	$687.0K	↓ 107.8%
Investing Cash Flow	$-2.2M	↑ 128.82%
Financing Cash Flow	$4.1M	↓ 16.21%

	FY19	Y/Y Change
Operating Cash Flow	$950.0K	↑ 38.28%
Investing Cash Flow	$-1.8M	↓ 16.64%
Financing Cash Flow	$-1.0M	↓ 124.35%

	FY20	Y/Y Change
Operating Cash Flow	$-1.1M	↓ 215.79%
Investing Cash Flow	$-981.0K	↓ 46.48%
Financing Cash Flow	$1.4M	↓ 242.45%

	FY21	Y/Y Change
Operating Cash Flow	$5.1M	↓ 562.0%
Investing Cash Flow	$-18.7M	↑ 1804.79%
Financing Cash Flow	$51.5M	↑ 3491.77%

	FY22	Y/Y Change
Operating Cash Flow	$1.7M	↓ 66.45%
Investing Cash Flow	$-1.7M	↓ 90.67%
Financing Cash Flow	$54.1M	↑ 5.19%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$4.6M	↓ 155.59%
Investing Cash Flow	$-1.2M	↓ 99.05%
Financing Cash Flow	$189.0K	↓ 99.7%

Harrow Technicals Summary

Sell

Neutral

Buy

Harrow is currently in a neutral trading position according to technical analysis indicators.

Harrow (HROW) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Harrow Inc	-14.86%	-34.44%	132.1%	271.81%	211.39%
Intra-cellular Therapies, Inc.	3.38%	81.15%	98.68%	146.46%	588.66%
Haleon Plc Spon Ads	10.71%	2.13%	26.53%	42.24%	42.24%
Zoetis Inc.	-3.04%	-10.5%	-9.01%	-11.21%	28.74%
Neurocrine Biosciences Inc.	-25.31%	-6.07%	-13.91%	29.45%	28.72%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Harrow Inc	NA	NA	NA	-0.44	-0.5	-0.02	NA	1.63
Intra-cellular Therapies, Inc.	NA	NA	0.0	0.13	-0.09	-0.07	NA	10.81
Haleon Plc Spon Ads	26.35	26.35	1.92	0.36	0.09	0.04	0.02	1.8
Zoetis Inc.	31.17	31.17	3.01	6.07	0.51	0.15	0.01	10.64
Neurocrine Biosciences Inc.	34.6	34.6	0.27	6.44	0.14	0.1	NA	26.05

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Harrow Inc	Buy	$929.9M	211.39%	NA	-19.75%
Intra-cellular Therapies, Inc.	Buy	$14.0B	588.66%	NA	-10.97%
Haleon Plc Spon Ads	Buy	$47.7B	42.24%	26.35	12.84%
Zoetis Inc.	Buy	$76.1B	28.74%	31.17	26.86%
Neurocrine Biosciences Inc.	Buy	$11.4B	28.72%	34.6	14.49%

About Harrow

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. Further, the company has collaboration with Asembia to enhance provider and patient experience through nationwide digital services and hub support for harrow's branded eyecare products. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

Organization	Harrow
Employees	315
CEO	Mr. Mark L. Baum J.D.
Industry	Health Technology

Management People of Harrow

Name	Title
Mr. Mark L. Baum J.D.	CEO & Chairman of the Board
Mr. Andrew R. Boll C.F.A., C.M.A.	CFO & Corporate Secretary
Mr. John P. Saharek MBA	President & CEO of Harrow's ImprimisRx Division
Dr. Amir H. Shojaei Ph.D., Pharm.D.	Chief Scientific Officer
Ms. Jamie Webb	Director of Communications & Investor Relations
Mr. Brett A. Burrell	Vice President of Legal & Compliance
Ms. Kim Barratt	Chief Talent Officer
Dr. Mark A. Mannebach Ph.D., R.Ph.	Head of Regulatory Affairs & Pharmacovigilance
Mr. Greg DiPasquale	Senior VP & Head of Commercial

Important FAQs about investing in HROW Stock from India :

What is Harrow share price today?

Harrow share price today stands at $26.25, Open: $25.90 ; Previous Close: $26.11 ; High: $26.27 ; Low: $25.21 ; 52 Week High: $59.23 ; 52 Week Low: $9.30.

The stock opens at $25.90, after a previous close of $26.11. The stock reached a daily high of $26.27 and a low of $25.21, with a 52-week high of $59.23 and a 52-week low of $9.30.

Can Indians buy Harrow shares?

Yes, Indians can invest in the Harrow (HROW) from India.

With INDmoney, you can buy Harrow at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Harrow at zero transaction cost.

How can I buy Harrow shares from India?

It is very easy to buy Harrow from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Harrow (HROW) be purchased?

Yes, you can buy fractional shares of Harrow with INDmoney app.

What are the documents required to start investing in Harrow stocks?

To start investing in Harrow, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.